General Information
Drug ID
DR00318
Drug Name
Pemetrexed
Synonyms
(2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID; Alimta; Alimta (TN); LY 231,514; LY 231514; LY-231,514; LY-2315; LY-231514; LY231514; LYA; N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid; N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-d-glutamic acid; Pemetrexed (INN); Pemetrexed [INN:BAN]
Drug Type
Small molecular drug
Indication Malignant pleural mesothelioma [ICD11: 2C26.0] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=135410875"></iframe>
3D MOL 2D MOL
Formula
C20H21N5O6
Canonical SMILES
C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O
InChI
InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m1/s1
InChIKey
WBXPDJSOTKVWSJ-CYBMUJFWSA-N
CAS Number
CAS 150399-23-8
Pharmaceutical Properties Molecular Weight 427.417 Topological Polar Surface Area 187
Heavy Atom Count 31 Rotatable Bond Count 9
Hydrogen Bond Donor Count 6 Hydrogen Bond Acceptor Count 7
PubChem CID
135410875
PubChem SID
104321790 , 117542033 , 126665655 , 134337377 , 134338975 , 134339784 , 134457174 , 135945851 , 137002681 , 152035380 , 160963987 , 175437774 , 177748645 , 178103443 , 189306395 , 223392020 , 223658518 , 223705327 , 224164966 , 226399254 , 250180319 , 252216021 , 43118181 , 46505640 , 50064379 , 50524509 , 53788923 , 57314144 , 90342403
ChEBI ID
CHEBI:63616
TTD Drug ID
D0Y4GO
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
FLOT1 Transporter Info Folate transporter 1 Substrate [3]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [4]
MRP5 Transporter Info Multidrug resistance-associated protein 5 Substrate [5]
OATP2B1 Transporter Info Organic anion transporting polypeptide 2B1 Substrate [6]
PCFT Transporter Info Proton-coupled folate transporter Substrate [7]
Drug-Transporter Activity Data
Drug-Transporter Activity Data FLOT1 Transporter Info Km = 0.2 microM Human liver cancer cells (HepG2)-FLOT1 [8]
MRP5 Transporter Info Km = 281 microM Human embryonic kidney cells (HEK293)-MRP5 [5]
PCFT Transporter Info Km = 0.2 microM Human liver cancer cells (HepG2)-PCFT [7]
References
1 Pemetrexed was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 pH-Dependent transport of pemetrexed by breast cancer resistance protein. Drug Metab Dispos. 2011 Sep;39(9):1478-85.
3 Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. Curr Top Membr. 2014;73:175-204.
4 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
5 Kinetic validation of the use of carboxydichlorofluorescein as a drug surrogate for MRP5-mediated transport. Eur J Pharm Sci. 2006 Apr;27(5):524-32.
6 Substrate- and pH-specific antifolate transport mediated by organic anion-transporting polypeptide 2B1 (OATP2B1-SLCO2B1). Mol Pharmacol. 2012 Feb;81(2):134-42.
7 The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol. 2008 Sep;74(3):854-62.
8 Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat. 2012 Aug;15(4):183-210.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.